In a filing, Allogene Therapeutics Inc revealed its Director MESSEMER DEBORAH M. acquired Company’s shares for reported $52391.0 on Jun 10 ’25. In the deal valued at $1.42 per share,36,885 shares were bought.
Then, Yoshiyama Annie sold 9,601 shares, generating $13,537 in total proceeds. Upon selling the shares at $1.41, the SVP, Finance now owns 130,663 shares.
Before that, Yoshiyama Annie bought 9,601 shares. Allogene Therapeutics Inc shares valued at $13,537 were divested by the Officer at a price of $1.41 per share.
Citizens JMP downgraded its Allogene Therapeutics Inc [ALLO] rating to a Mkt perform from a a Mkt outperform in a research note published recently. A number of analysts have revised their coverage, including Citizens JMP’s analysts, who increased its forecast for the stock in mid March from “a Mkt perform” to “a Mkt outperform”. Piper Sandler started covering the stock on May 31, 2024. It rated ALLO as “an Overweight”.
Price Performance Review of ALLO
On Tuesday, Allogene Therapeutics Inc [NASDAQ:ALLO] saw its stock jump 3.55% to $1.46. Over the last five days, the stock has gained 8.15%. Allogene Therapeutics Inc shares have fallen nearly -31.46% since the year began. Nevertheless, the stocks have fallen -39.42% over the past one year.
How much short interest is there in Allogene Therapeutics Inc?
A steep rise in short interest was recorded in Allogene Therapeutics Inc stocks on 2025-05-15, dropping by -5.45 million shares to a total of 27.36 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 32.81 million shares. There was a decline of -19.92%, which implies that there is a negative sentiment for the stock.
